Emergent BioSolutions Inc. EBS
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 81.85% | -2,750.00% | 112.45% | -206.64% | 526.67% |
| Total Depreciation and Amortization | -29.17% | 2.13% | -9.62% | 11.11% | -0.43% |
| Total Amortization of Deferred Charges | 0.00% | -11.11% | -30.77% | 4.00% | 4.17% |
| Total Other Non-Cash Items | -107.69% | 1,769.50% | -164.98% | 985.00% | 162.50% |
| Change in Net Operating Assets | 635.63% | 52.32% | -163.17% | 200.74% | -185.06% |
| Cash from Operations | 78.43% | 265.98% | -143.50% | 3,478.26% | -102.16% |
| Capital Expenditure | -57.14% | 12.50% | 38.46% | -14.71% | -17.24% |
| Sale of Property, Plant, and Equipment | 2,600.00% | -- | -- | -- | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 104.96% | -- | -- | -- | -100.00% |
| Cash from Investing | 108.80% | -2,079.17% | 38.46% | -14.71% | -119.77% |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | 54.33% | -- | -- | -1,430.43% | -- |
| Issuance of Common Stock | -90.00% | 150.00% | -66.67% | 500.00% | -71.43% |
| Repurchase of Common Stock | 96.81% | 20.34% | -24.21% | -3.26% | -29.58% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | -- | -- | -- |
| Cash from Financing | -181.56% | -114.04% | 89.99% | -616.35% | -148.44% |
| Foreign Exchange rate Adjustments | -- | -- | -- | 100.00% | -120.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 274.76% | 56.72% | -18.70% | -83.94% | -118.44% |